Getagraph.com logo
S&P 500
(0.12%) 5 187.03 points
Dow Jones
(0.06%) 38 874 points
Nasdaq
(-0.03%) 16 344 points
Oil
(0.22%) $78.65
Gas
(0.59%) $2.21
Gold
(-0.30%) $2 324.10
Silver
(-0.32%) $27.53
Platinum
(2.43%) $988.35
USD/EUR
(0.16%) $0.930
USD/NOK
(0.86%) $10.92
USD/GBP
(0.43%) $0.799
USD/RUB
(-0.03%) $91.32

Realtime updates for Barinthus Biotherapeutics [BRNS]

Exchange: NASDAQ Global Market Sector: Healthcare Industry: Biotechnology
Upcoming Earnings Alert

3 days till quarter result
(bmo 2024-05-10)

Expected move: +/- 0.00%

Last Updated7 May 2024 @ 12:39
25% discount on Stockinvest.us - Use code: Podcast

8.84% $ 2.40

Live Chart Being Loaded With Signals

Commentary (7 May 2024 @ 12:39):

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in developing novel T cell immunotherapeutics to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer...

Stats
Today's Volume 1 664.00
Average Volume 24 827.00
Market Cap 92.74M
EPS $-0.450 ( 2024-03-22 )
Next earnings date ( $-0.640 ) 2024-05-10
Last Dividend $0 ( N/A )
Next Dividend $0 ( N/A )
P/E 0
ATR14 $0.0390 (1.63%)

Barinthus Biotherapeutics Correlation

10 Most Positive Correlations
10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Barinthus Biotherapeutics Financials

Annual 2023
Revenue: $805 108
Gross Profit: $802 000 (99.61 %)
EPS: $-1.920
FY 2023
Revenue: $805 108
Gross Profit: $802 000 (99.61 %)
EPS: $-1.920
FY 2022
Revenue: $44.70M
Gross Profit: $44.70M (100.00 %)
EPS: $0.140

Financial Reports:

No articles found.

Barinthus Biotherapeutics

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in developing novel T cell immunotherapeutics to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. It is advancing a pipeline of product candidates across a range of therapeutic areas, including VTP-300, an immunotherapeutic candidate designed as a potential component of a functional cure for chronic HBV infection; VTP-200, a non-surgical product candidate for persistent high-risk human papillomavirus (HPV); VTP-1000, an autoimmune candidate designed to utilize the SNAP-TI platform to treat patients with celiac disease; VTP-850, a second-generation immunotherapeutic candidate designed to treat recurrent prostate cancer; and VTP-1100, a preclinical cancer candidate designed to utilize the SNAP-CI platform to treat patients with HPV-related cancer. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Harwell, the United Kingdom.

About Live Signals

The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.

The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators